BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood Reviews 2018;32:300-11. [DOI: 10.1016/j.blre.2018.02.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Prosdocimi M, Zuccato C, Cosenza LC, Borgatti M, Lampronti I, Finotti A, Gambari R. A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs. Wellcome Open Res 2022;7:150. [DOI: 10.12688/wellcomeopenres.17845.3] [Reference Citation Analysis]
2 Kuo KHM, Layton DM, Lal A, Al-samkari H, Bhatia J, Kosinski PA, Tong B, Lynch M, Uhlig K, Vichinsky EP. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study. The Lancet 2022;400:493-501. [DOI: 10.1016/s0140-6736(22)01337-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Prosdocimi M, Zuccato C, Cosenza LC, Borgatti M, Lampronti I, Finotti A, Gambari R. A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs. Wellcome Open Res 2022;7:150. [DOI: 10.12688/wellcomeopenres.17845.2] [Reference Citation Analysis]
4 Prosdocimi M, Zuccato C, Cosenza LC, Borgatti M, Lampronti I, Finotti A, Gambari R. A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs. Wellcome Open Res 2022;7:150. [DOI: 10.12688/wellcomeopenres.17845.1] [Reference Citation Analysis]
5 Abbasalipour M, Khosravi MA, Zeinali S, Khanahmad H, Azadmanesh K, Karimipoor M. Lentiviral vector containing beta-globin gene for beta thalassemia gene therapy. Gene Reports 2022. [DOI: 10.1016/j.genrep.2022.101615] [Reference Citation Analysis]
6 Matsagos S, Verigou E, Kourakli A, Alexis S, Vrakas S, Argyropoulou C, Lazaris V, Spyropoulou P, Labropoulou V, Georgara N, Lykouresi M, Karakantza M, Alepi C, Symeonidis A. High Frequency of Post-Transfusion Microchimerism Among Multi-Transfused Beta-Thalassemic Patients. Front Med (Lausanne) 2022;9:845490. [PMID: 35252277 DOI: 10.3389/fmed.2022.845490] [Reference Citation Analysis]
7 Aziz A, Baharin MF, Fauzi MY, Abdul Hamid FS, Nadarajaw T, Ahmad R, Hashim H. Rare cause of transfusion-dependent hemolytic anemia: A case report of HbE/Hb Nottingham and literature review. Pediatr Blood Cancer 2022;:e29629. [PMID: 35253358 DOI: 10.1002/pbc.29629] [Reference Citation Analysis]
8 Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S. A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. Sci Rep 2022;12:2752. [PMID: 35177777 DOI: 10.1038/s41598-022-06774-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Bulgurcu SC, Canbolat Ayhan A, Emeksiz HC, Ovali F. Assessment of the Nutritional Status, Bone Mineralization, and Anthropometrics of Children with Thalassemia Major. Medeni Med J 2021;36:325-32. [PMID: 34939399 DOI: 10.4274/MMJ.galenos.2021.66915] [Reference Citation Analysis]
10 Chen JM, Zhu WJ, Liu J, Wang GZ, Chen XQ, Tan Y, Xu WW, Qu LW, Li JY, Yang HJ, Huang L, Cai N, Wang WD, Huang K, Xu JQ, Li GH, He S, Luo TY, Huang Y, Liu SH, Wu WQ, Lu QY, Zhou MG, Chen SY, Li RL, Hu ML, Huang Y, Wei JH, Li JM, Chen SJ, Zhou GB. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial. Signal Transduct Target Ther 2021;6:405. [PMID: 34795208 DOI: 10.1038/s41392-021-00811-0] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Madan U, Bhasin H, Dewan P, Madan J. Improving Ineffective Erythropoiesis in Thalassemia: A Hope on the Horizon. Cureus 2021;13:e18502. [PMID: 34754662 DOI: 10.7759/cureus.18502] [Reference Citation Analysis]
12 Taher AT, Bou-Fakhredin R, Kattamis A, Viprakasit V, Cappellini MD. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Rev Hematol 2021;14:897-909. [PMID: 34493145 DOI: 10.1080/17474086.2021.1977116] [Reference Citation Analysis]
13 Taher AT, Cappellini MD. Luspatercept for β-thalassemia: beyond red blood cell transfusions. Expert Opin Biol Ther 2021;21:1363-71. [PMID: 34404288 DOI: 10.1080/14712598.2021.1968825] [Reference Citation Analysis]
14 Porter J, Taher A, Viprakasit V, Kattamis A, Coates TD, Garbowski M, Dürrenberger F, Manolova V, Richard F, Cappellini MD. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development. Expert Rev Hematol 2021;14:633-44. [PMID: 34324404 DOI: 10.1080/17474086.2021.1935854] [Reference Citation Analysis]
15 Zhou X, Chen T, Zhang Q, Qi M, Zhang L, Du J, Chi H, Shen B, Xu X, Lu Y. De novo HBB frameshift mutation in a patient with dominant β-thalassemia major. Int J Lab Hematol 2021. [PMID: 34323379 DOI: 10.1111/ijlh.13669] [Reference Citation Analysis]
16 Hindawi S, Badawi M, Elfayoumi R, Elgemmezi T, Al Hassani A, Raml M, Alamoudi S, Gholam K. The value of transfusion of phenotyped blood units for thalassemia and sickle cell anemia patients at an academic center. Transfusion 2020;60 Suppl 1:S15-21. [PMID: 32134130 DOI: 10.1111/trf.15682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lam JCM, Lee SY, Koh PL, Fong SZ, Abdul-kadir NI, Lim CY, Zhang X, Bhattacharyya R, Soh SY, Chan MY, Tan AM, Kuperan P, Ang AL. Clinical and health-related quality of life outcomes of transfusion-dependent thalassaemia patients in Singapore. Blood Cells, Molecules, and Diseases 2021;88:102547. [DOI: 10.1016/j.bcmd.2021.102547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Shafie AA, Chhabra IK, Wong JHY, Mohammed NS. Mapping PedsQL™ Generic Core Scales to EQ-5D-3L utility scores in transfusion-dependent thalassemia patients. Eur J Health Econ 2021;22:735-47. [PMID: 33860379 DOI: 10.1007/s10198-021-01287-z] [Reference Citation Analysis]
19 Babu T, Panachiyil GM, Sebastian J, Ravi MD. Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review. Indian J Pharmacol 2020;52:514-9. [PMID: 33666193 DOI: 10.4103/ijp.IJP_333_19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Brusson M, Miccio A. Genome editing approaches to β-hemoglobinopathies. Prog Mol Biol Transl Sci 2021;182:153-83. [PMID: 34175041 DOI: 10.1016/bs.pmbts.2021.01.025] [Reference Citation Analysis]
21 Wang F, Ling L, Yu D. MicroRNAs in β-thalassemia. Am J Med Sci 2021;362:5-12. [PMID: 33600783 DOI: 10.1016/j.amjms.2021.02.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Antoniou P, Miccio A, Brusson M. Base and Prime Editing Technologies for Blood Disorders. Front Genome Ed 2021;3:618406. [DOI: 10.3389/fgeed.2021.618406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Angastiniotis M, Petrou M, Loukopoulos D, Modell B, Farmakis D, Englezos P, Eleftheriou A. The Prevention of Thalassemia Revisited: A Historical and Ethical Perspective by the Thalassemia International Federation. Hemoglobin 2021;45:5-12. [PMID: 33461349 DOI: 10.1080/03630269.2021.1872612] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Khan AM, Al-Sulaiti AM, Younes S, Yassin M, Zayed H. The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review. Expert Rev Hematol 2021;14:109-22. [PMID: 33317346 DOI: 10.1080/17474086.2021.1860003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Abd El-Samee H, Bassiouny N, Nabih N. Impact of activated monocyte and endothelial dysfunction on coagulopathy in Egyptian adult beta thalassemic patients. Hematol Rep 2020;12:8365. [PMID: 33282163 DOI: 10.4081/hr.2020.8365] [Reference Citation Analysis]
26 Yasara N, Wickramarathne N, Mettananda C, Manamperi A, Premawardhena A, Mettananda S. Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial. BMJ Open 2020;10:e041958. [PMID: 33109679 DOI: 10.1136/bmjopen-2020-041958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Trakarnsanga K, Tipgomut C, Metheetrairut C, Wattanapanitch M, Khuhapinant A, Poldee S, Kurita R, Nakamura Y, Srisawat C, Frayne J. Generation of an immortalised erythroid cell line from haematopoietic stem cells of a haemoglobin E/β-thalassemia patient. Sci Rep 2020;10:16798. [PMID: 33033327 DOI: 10.1038/s41598-020-73991-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
28 Breveglieri G, Pacifico S, Zuccato C, Cosenza LC, Sultan S, D'Aversa E, Gambari R, Preti D, Trapella C, Guerrini R, Borgatti M. Discovery of Novel Fetal Hemoglobin Inducers through Small Chemical Library Screening. Int J Mol Sci 2020;21:E7426. [PMID: 33050052 DOI: 10.3390/ijms21197426] [Reference Citation Analysis]
29 Hamed EM, Meabed MH, Aly UF, Hussein RRS. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia. Curr Drug Targets 2019;20:1603-23. [PMID: 31362654 DOI: 10.2174/1389450120666190726155733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WWMP. Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. Mol Ther Methods Clin Dev 2020;18:532-57. [PMID: 32775490 DOI: 10.1016/j.omtm.2020.06.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
31 Bewersdorf JP, Taher AT, Zeidan AM. No child with a transfusion-dependent haemoglobinopathy left unchelated: are we there yet? Lancet Haematol 2020;7:e429-30. [PMID: 32470430 DOI: 10.1016/S2352-3026(20)30114-9] [Reference Citation Analysis]
32 Terán MM, Mónaco ME, Lazarte SS, Haro C, Ledesma Achem E, Asensio NA, Issé BA. Genetic Regulation of Redox Balance in β-Thalassemia Trait. Hemoglobin 2020;44:122-7. [PMID: 32448013 DOI: 10.1080/03630269.2020.1765794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Ricchi P, Meloni A, Costantini S, Spasiano A, Cinque P, Gargiulo B, Pepe A, Filosa A. Red blood cell consumption in a large cohort of patients with thalassaemia: a retrospective analysis of main predictors. Ann Hematol 2020;99:1209-15. [PMID: 32363417 DOI: 10.1007/s00277-020-04047-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Bou-fakhredin R, Tabbikha R, Daadaa H, Taher AT. Emerging therapies in β-thalassemia: toward a new era in management. Expert Opinion on Emerging Drugs 2020;25:113-22. [DOI: 10.1080/14728214.2020.1752180] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
35 Casu C, Chessa R, Liu A, Gupta R, Drakesmith H, Fleming R, Ginzburg YZ, MacDonald B, Rivella S. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major. Haematologica 2020;105:1835-44. [PMID: 31582543 DOI: 10.3324/haematol.2018.212589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
36 Cappellini MD, Kattamis A, Viprakasit V, Sutcharitchan P, Pariseau J, Laadem A, Jessent-Ciaravino V, Taher A. Quality of life in patients with β-thalassemia: A prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand. Am J Hematol 2019;94:E261-4. [PMID: 31321793 DOI: 10.1002/ajh.25584] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
37 Mettananda S, Yasara N, Fisher CA, Taylor S, Gibbons R, Higgs D. Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia. Sci Rep 2019;9:11649. [PMID: 31406232 DOI: 10.1038/s41598-019-48204-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
38 Mettananda S, Pathiraja H, Peiris R, Bandara D, de Silva U, Mettananda C, Premawardhena A. Health related quality of life among children with transfusion dependent β-thalassaemia major and haemoglobin E β-thalassaemia in Sri Lanka: a case control study. Health Qual Life Outcomes 2019;17:137. [PMID: 31395066 DOI: 10.1186/s12955-019-1207-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
39 Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood Rev 2019;37:100588. [PMID: 31324412 DOI: 10.1016/j.blre.2019.100588] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
40 Iolascon A, De Franceschi L, Muckenthaler M, Taher A, Rees D, de Montalembert M, Rivella S, Eleftheriou A, Cappellini MD. EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. Hemasphere 2019;3:e208. [PMID: 31723835 DOI: 10.1097/HS9.0000000000000208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
41 El-beshlawy A, El-ghamrawy M. Recent trends in treatment of thalassemia. Blood Cells, Molecules, and Diseases 2019;76:53-8. [DOI: 10.1016/j.bcmd.2019.01.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
42 Kolliopoulou A, Siamoglou S, John A, Sgourou A, Kourakli A, Symeonidis A, Vlachaki E, Chalkia P, Theodoridou S, Ali BR, Katsila T, Patrinos GP, Papachatzopoulou A. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study. Hemoglobin 2019;43:27-33. [PMID: 31039620 DOI: 10.1080/03630269.2019.1597732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
43 Angastiniotis M, Lobitz S. Thalassemias: An Overview. Int J Neonatal Screen 2019;5:16. [PMID: 33072976 DOI: 10.3390/ijns5010016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
44 Mettananda S, Pathiraja H, Peiris R, Wickramarathne N, Bandara D, de Silva U, Mettananda C, Premawardhena A. Blood transfusion therapy for β-thalassemia major and hemoglobin E β-thalassemia: Adequacy, trends, and determinants in Sri Lanka. Pediatr Blood Cancer 2019;66:e27643. [PMID: 30697927 DOI: 10.1002/pbc.27643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
45 Oved JH, Wang Y, Barrett DM, Levy EM, Huang Y, Monos DS, Grupp SA, Bunin NJ, Olson TS. CD3+/CD19+ Depleted Matched and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplant with Targeted T Cell Addback Is Associated with Excellent Outcomes in Pediatric Patients with Nonmalignant Hematologic Disorders. Biol Blood Marrow Transplant 2019;25:549-55. [PMID: 30312755 DOI: 10.1016/j.bbmt.2018.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Lidonnici MR, Paleari Y, Tiboni F, Mandelli G, Rossi C, Vezzoli M, Aprile A, Lederer CW, Ambrosi A, Chanut F, Sanvito F, Calabria A, Poletti V, Mavilio F, Montini E, Naldini L, Cristofori P, Ferrari G. Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia. Mol Ther Methods Clin Dev 2018;11:9-28. [PMID: 30320151 DOI: 10.1016/j.omtm.2018.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
47 Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood 2018;132:1781-91. [PMID: 30206117 DOI: 10.1182/blood-2018-06-818187] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]